Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus-containing versus mTOR-inhibitor-free immunosuppression after liver transplantation for hepatocellular carcinoma
2005-005362-36Phase 3Completed
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus in hepatocellular carcinoma (HCC) and Hepatic transplant rejection (LTR) (2 arms), sponsored by Universitätsklinikum Regensburg. Primary endpoint: HCC recurrence-free patient survival. Started Apr 2006; status: completed.
02
Drugs
sirolimus
03
Conditions
hepatocellular carcinoma (HCC)Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on 2005-005362-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005362-36.